Aflac (AFL) Earnings Date & Reports

Key Takeaways

• Consensus estimates point to adjusted earnings per share (EPS) of approximately $1.77 for Q2 2026, slightly below the $1.78 reported in the same quarter last year.
• Revenue expectations center around $4.24 billion to $4.25 billion, which would mark a decline from $4.54 billion in Q2 2025, partly reflecting currency headwinds in the Japan segment.
• Japan sales momentum remains a bright spot after Q1 delivered 25.5% annualized premium sales growth, driven by new products including Anshin Palette, Miraito, and Tsumitasu.
• Capital return strategy continues to anchor the investment case, with the company returning $1.3 billion to shareholders in Q1 alone through buybacks and dividends.
• Aflac stock has climbed over 29% in the past 52 weeks and is trading near all-time highs, raising the bar for an earnings beat to sustain the rally.
• Analyst consensus remains a cautious Hold, with an average 12-month price target around $116 to $118 — below current trading levels near $127.

Earnings Context and Why It Matters

Aflac Incorporated (NYSE: AFL), the Fortune 500 supplemental insurance giant operating across the United States and Japan, is scheduled to report its second-quarter 2026 financial results after the market closes on Thursday, August 6, 2026. A conference call with executive management will follow on Friday, August 7. This report arrives at a pivotal moment for Aflac: the company's stock has outperformed the broader market significantly, yet Q1 2026 results revealed a rare EPS miss against consensus, stoking debate about whether recent momentum is sustainable. With aggressive share buybacks, a 44-year streak of consecutive dividend increases, and ongoing product innovation in both the U.S. and Japan, investors will be closely scrutinizing whether top-line growth and margin trends can support the stock's elevated valuation.

Earnings Expectations

Wall Street analysts expect Aflac to report adjusted earnings per share of roughly $1.77 for the second quarter of 2026, according to consensus estimates compiled from multiple research firms. This would represent a marginal decline from the $1.78 per share reported in the year-ago period (Q2 2025). Revenue expectations cluster around $4.24 billion to $4.25 billion, which would mark a year-over-year decline from the $4.54 billion recorded in Q2 2025. It is worth noting that Aflac has surpassed consensus EPS estimates in two of the last four quarters and missed in the other two, most recently posting adjusted EPS of $1.75 in Q1 2026 — $0.05 below the consensus estimate of $1.80, despite revenue of $4.24 billion coming in above expectations.

Beyond the headline figures, investors and analysts will be paying close attention to several operating metrics. For the Japan segment, the benefit ratio — a key measure of claims costs relative to premiums — is guided to remain within the 60% to 63% range for the full year, while the expense ratio is expected to land between 20% and 23%. In the U.S., the benefit ratio is guided at 48% to 52%, with an expense ratio of 36% to 39%. Foreign exchange (FX) movements between the Japanese yen and the U.S. dollar remain a persistent variable, as a significant portion of Aflac's earnings originate in Japan. Adjusted EPS excluding currency remeasurement reached $1.77 in Q1, suggesting a roughly $0.02 headwind from FX.

AI Screener

For investors looking to identify earnings-driven opportunities beyond Aflac, Tickeron's AI Screener offers a powerful solution. The AI Screener is an AI-powered stock and ETF discovery tool that enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven signals. Whether scanning for breakout candidates, earnings-season trade ideas, or long-term trend-following setups, the screener helps users surface relevant opportunities far more efficiently than manual research. With real-time data and an intuitive interface, it is designed to support both active traders and longer-term investors in navigating complex markets with greater confidence.

Market Reaction and Investor Sentiment

Investor sentiment heading into Aflac's Q2 report appears cautiously optimistic but divided. The stock has been a standout performer, gaining approximately 29% over the trailing 52 weeks and roughly 17% year-to-date through late July 2026, outpacing the S&P 500 by a wide margin. Shares recently traded near $127, close to the 52-week high of $130.22. However, the analyst community has adopted a guarded stance: the consensus rating sits at Hold, with an average 12-month price target of approximately $116 to $118 — implying that the stock may already reflect much of the good news. Two analysts carry Strong Buy ratings, two recommend Buy, seven are at Hold, and two assign Sell ratings. After the Q1 miss in April, the stock dipped roughly 2.7% in premarket trading, underscoring the market's sensitivity to earnings surprises. Key sentiment risks heading into Q2 include potential yen depreciation, softer-than-expected net investment income, and any deterioration in U.S. benefit ratios.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, several themes will shape the narrative for Aflac through the remainder of fiscal 2026. The most prominent is the trajectory of Japan's new product engine. Q1 saw annualized premium sales in Japan jump 25.5% year over year, driven by the Anshin Palette medical insurance product, Miraito cancer insurance, and Tsumitasu life insurance. Management has indicated a full-year Japan sales target of approximately ¥80 billion, up from ¥74 billion in 2025, which would represent continued healthy momentum. Sustaining this pace is central to offsetting gradual earned premium runoff in legacy blocks.

In the U.S. segment, group voluntary benefits have emerged as the growth leader, with group product sales up 12.4% in Q1, while the traditional agent-driven individual business remained relatively flat. Network dental and vision, along with group life and disability, are contributing to diversification. Investors will watch whether group momentum can compensate for the slower-growth core agency channel.

Capital deployment remains a critical pillar of the Aflac story. The company returned $1.3 billion to shareholders in Q1 through $1.0 billion in share repurchases and $315 million in dividends, and management has signaled continued tactical buyback activity. Aflac ended Q1 with an estimated regulatory solvency margin ratio (ESR) of approximately 227% in Japan (243% including unsecured subordinated promissory notes, or USP) and a combined risk-based capital (RBC) ratio of around 560% in the U.S., indicating substantial capital flexibility.

On the macroeconomic front, the yen-dollar exchange rate and the interest rate environment in both Japan and the United States will continue to influence investment income and segment-level profitability. The company's adjusted return on equity (ROE), excluding foreign currency remeasurement, stood at 16.4% in Q1, up 80 basis points year over year — a positive signal for capital efficiency, but one that needs to be sustained. Finally, Aflac's growing reinsurance franchise, including a recent block assumption from Japan Post Insurance through Aflac Re Bermuda, represents a longer-term earnings diversification opportunity, though the near-term financial impact is expected to be modest.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations